Walleye Trading’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.48M | Sell |
5,800
-9,400
| -62% | -$7.2M | 0.01% | 1200 |
|
|
2025
Q4 | $11.7M | Sell |
15,200
-300
| -2% | -$204K | 0.02% | 839 |
|
|
2025
Q3 | $8.72M | Buy |
15,500
+6,300
| +68% | +$3.56M | 0.01% | 966 |
|
|
2025
Q2 | $4.83M | Sell |
9,200
-1,800
| -16% | -$1M | 0.01% | 1231 |
|
|
2025
Q1 | $6.98M | Buy |
11,000
+3,800
| +53% | +$2.61M | 0.02% | 917 |
|
|
2024
Q4 | $5.13M | Buy |
7,200
+5,100
| +243% | +$4.28M | 0.01% | 1128 |
|
|
2024
Q3 | $2.21M | Buy |
2,100
+1,300
| +163% | +$1.45M | ﹤0.01% | 1619 |
|
|
2024
Q2 | $841K | Sell |
800
-1,900
| -70% | -$1.84M | ﹤0.01% | 2189 |
|
|
2024
Q1 | $2.6M | Sell |
2,700
-16,100
| -86% | -$15.3M | 0.01% | 1568 |
|
|
2023
Q4 | $16.5M | Buy |
18,800
+2,800
| +18% | +$2.31M | 0.04% | 539 |
|
|
2023
Q3 | $13.2M | Buy |
16,000
+200
| +1% | +$157K | 0.03% | 553 |
|
|
2023
Q2 | $11.4M | Sell |
15,800
-16,500
| -51% | -$12.7M | 0.03% | 533 |
|
|
2023
Q1 | $26.5M | Buy |
32,300
+5,000
| +18% | +$3.77M | 0.06% | 287 |
|
|
2022
Q4 | $19.7M | Sell |
27,300
-24,800
| -48% | -$18.3M | 0.06% | 360 |
|
|
2022
Q3 | $35.9M | Buy |
52,100
+21,700
| +71% | +$13.7M | 0.11% | 162 |
|
|
2022
Q2 | $18M | Buy |
30,400
+7,400
| +32% | +$4.81M | 0.06% | 360 |
|
|
2022
Q1 | $16.1M | Buy |
23,000
+19,400
| +539% | +$12.3M | 0.05% | 434 |
|
|
2021
Q4 | $2.27M | Sell |
3,600
-1,200
| -25% | -$738K | 0.01% | 1524 |
|
|
2021
Q3 | $2.9M | Sell |
4,800
-3,000
| -38% | -$1.86M | 0.01% | 1295 |
|
|
2021
Q2 | $4.36M | Buy |
7,800
+1,200
| +18% | +$608K | 0.02% | 886 |
|
|
2021
Q1 | $3.12M | Sell |
6,600
-12,800
| -66% | -$6.23M | 0.01% | 981 |
|
|
2020
Q4 | $9.37M | Buy |
19,400
+10,800
| +126% | +$5.83M | 0.04% | 423 |
|
|
2020
Q3 | $4.81M | Buy |
8,600
+7,000
| +438% | +$4.24M | 0.03% | 590 |
|
|
2020
Q2 | $998K | Sell |
1,600
-1,500
| -48% | -$851K | 0.01% | 1665 |
|
|
2020
Q1 | $1.51M | Sell |
3,100
-8,600
| -74% | -$3.55M | 0.01% | 1017 |
|
|
2019
Q4 | $4.39M | Buy |
11,700
+9,300
| +388% | +$3.13M | 0.03% | 646 |
|
|
2019
Q3 | $666K | Buy |
2,400
+300
| +14% | +$88.8K | 0.01% | 1908 |
|
|
2019
Q2 | $657K | Buy |
2,100
+100
| +5% | +$33.3K | 0.01% | 1965 |
|
|
2019
Q1 | $821K | Sell |
2,000
-1,700
| -46% | -$700K | 0.01% | 1840 |
|
|
2018
Q4 | $1.38M | Sell |
3,700
-9,900
| -73% | -$3.62M | 0.01% | 1381 |
|
|
2018
Q3 | $5.5M | Buy |
13,600
+7,800
| +134% | +$2.97M | 0.03% | 593 |
|
|
2018
Q2 | $2M | Sell |
5,800
-3,900
| -40% | -$1.22M | 0.01% | 1352 |
|
|
2018
Q1 | $3.34M | Buy |
9,700
+4,100
| +73% | +$1.43M | 0.02% | 779 |
|
|
2017
Q4 | $2.11K | Sell |
5,600
-2,700
| -33% | -$1.09M | 0.01% | 1259 |
|
|
2017
Q3 | $3.71K | Buy |
8,300
+7,800
| +1,560% | +$3.71M | 0.02% | 841 |
|
|
2017
Q2 | $245 | Buy |
500
+100
| +25% | +$43.8K | ﹤0.01% | 2969 |
|
|
2017
Q1 | $155 | Buy |
400
+300
| +300% | +$111K | ﹤0.01% | 3138 |
|
|
2016
Q4 | $37K | Sell |
100
-100
| -50% | -$38K | ﹤0.01% | 3810 |
|
|
2016
Q3 | $80K | Sell |
200
-9,300
| -98% | -$3.73M | ﹤0.01% | 3457 |
|
|
2016
Q2 | $3.32M | Sell |
9,500
-1,400
| -13% | -$539K | 0.02% | 683 |
|
|
2016
Q1 | $3.93M | Buy |
10,900
+10,300
| +1,717% | +$4.24M | 0.03% | 489 |
|
|
2015
Q4 | $324K | Buy |
600
+100
| +20% | +$54.2K | ﹤0.01% | 2236 |
|
|
2015
Q3 | $235K | Sell |
500
-700
| -58% | -$376K | ﹤0.01% | 2224 |
|
|
2015
Q2 | $612K | Buy |
+1,200
| New | +$586K | 0.01% | 1494 |
|
Other funds holding REGN
VCM
N
Walleye Trading's REGN Position: Q1 2026 in Review
Walleye Trading reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, selling an estimated $1.9M and leaving 10,390 shares worth $8.03M. The position accounts for 0.01% of the portfolio, ranked #899.
Walleye Trading first reported a position in REGN in Q3 2013 and has held it in 35 quarters since. The position peaked at $12.5M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Walleye Trading held 10,390 shares of Regeneron Pharmaceuticals worth $8.03M as of Q1 2026.
- Walleye Trading sold 2,482 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.9M.
- Regeneron Pharmaceuticals made up 0.01% of Walleye Trading's portfolio in Q1 2026, its #899 holding.
- Walleye Trading first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 35 quarters since.
- Walleye Trading's Regeneron Pharmaceuticals position peaked at $12.5M in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.